Kyverna Therapeutics said multiple abstracts on its CD19 CAR T-cell therapy miv-cel (KYV-101) were selected for presentation at the American Academy of Neurology Annual Meeting in April 2026. The company plans a late-breaking oral presentation of the primary analysis from the KYSA-8 registrational Phase 2 trial in stiff person syndrome, and an oral presentation with updated Phase 2 data from the KYSA-6 study in generalized myasthenia gravis. It will also present posters on a real-world natural history study in stiff person syndrome and on the Phase 3 design of KYSA-6 comparing KYV-101 with ongoing standard-of-care immunosuppressive therapy; these results and study details will be presented in the future at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.